Walgreens Boots Alliance, Inc. WBA wholly-owned subsidiary — AllianceRx Walgreens Pharmacy — is selected as the exclusive distributor of Mycovia Pharmaceuticals’ VIVJOA (oteseconazole). Walgreens specialty pharmacy patients now have exclusive access to 240+ limited distribution drugs, which are available through Walgreens specialty pharmacy.

The latest development will bolster Walgreens’ Speciality Pharmacy business.

More on the News

Mycovia Pharmaceuticals’ VIVJOA is the first FDA-approved medicine to minimize the occurrence of recurrent vulvovaginal candidiasis (RVVC) in postmenopausal women or those who are not of reproductive age.

In addition to VIVJOA, AllianceRx Walgreens Pharmacy and certain community-based specialty pharmacies offer a few more limited-distribution medications, such as Augtyro (repotrectinib), an oral prescription medicine used to treat non-small cell lung cancer (NSCLC) in adults.

Image Source: Zacks Investment Research

It also includes Regeneron's Eylea HD (aflibercept) Injection, which has been approved to treat patients with neovascular (wet) age-related macular degeneration, diabetic macular edema and diabetic retinopathy.

Benefits of Access to VIVJOA

According to Walgreens management, Mycovia's selection of Walgreens as the exclusive specialty pharmacy partner of VIVJOA demonstrates the meticulous care and control of this drug offered by Walgreens specialty pharmacists. It's not only about how the company treats its patients but also about how it helps clinicians by putting their patients on therapy faster.

With the addition of this medication, Walgreens' enterprise specialty now has one of the biggest numbers of exclusive limited distribution pharmaceuticals among specialty pharmacies in the United States.

Industry Prospects

Per a report by Mordor Intelligence, the specialty pharmaceuticals market is expected to witness a CAGR of 35.4% during the period 2022-2027. The factors propelling the studied market growth are the increasing prevalence of chronic and rare diseases and growing research and development activities. New drug launches, approvals and strategic initiatives by key market players are expected to contribute to market growth.

Other Developments in the Pharmacy Segment

In December 2023, Walgreens’ Wholly-owned subsidiary — AllianceRx Walgreens Pharmacy — announced that it would distribute Tarsus Pharmaceuticals-manufactured XDEMVY (lotilaner ophthalmic solution) 0.25%. AllianceRx Walgreens is one of the four specialty pharmacies selected to distribute the FDA-approved treatment for Demodex blepharitis (DB), a highly prevalent eyelid disease that impacts almost 25 million eye care patients in the United States.